Skip to content

Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was downgraded by Zacks  from a “buy” rating to a “hold” rating in a research note provided to financiers on Thursday, records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It focuses on uncovering and also creating little molecule medicine prospects to deal with cancer cells. The Firm‘s items under various phases of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research analysts also just recently talked about the firm. Noble Financial reissued a “purchase” score and provided a $11.00 price goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and also set a “purchase” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day relocating ordinary price of $2.90 and a two-hundred day relocating ordinary rate of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) profits per share for the quarter, covering analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also a negative web margin of 8,294.27%. The company had profits of $0.06 million throughout the quarter, contrasted to the agreement quote of $0.06 million. Throughout the very same quarter in the prior year, the company published ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will certainly post -1.18 EPS for the existing year.

A variety of hedge funds have just recently bought and sold shares of ONTX. GSA Resources Partners LLP got a brand-new placement in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Resources Management LP got a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP purchased a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional investors have 13.36% of the company’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which engages in the recognition and development of oncology therapeutics. It focuses on discovering and also developing tiny molecule medication prospects to deal with cancer. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).

To find out more about research offerings from Zacks Investment Research, browse through

This immediate news alert was generated by narrative science modern technology and also monetary data from Market in order to provide readers with the fastest as well as most accurate reporting. This story was reviewed by Market’s editorial team prior to publication. 



Before you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market monitors Wall Street’s premier and best executing research analysts and also the stocks they recommend to their clients each day. Market has actually determined the five stocks that top analysts are quietly murmuring to their clients to buy now prior to the more comprehensive market catches on … and Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” ranking amongst analysts, top-rated analysts believe these five stocks are better acquires.